Semax Dosage (10 mg Vial) Protocol

Supplies Needed

Use one complete set of measured and sterile research supplies for each prepared Semax 10 mg nasal bottle.

• Semax 10 mg research vial: One vial per prepared bottle. The product gallery below links to the existing Semax 10 mg supplier page^[8].
• Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
• Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
• Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
• Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
• Sterile transfer needle: Required when the peptide vial uses a rubber septum.
• Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
• Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
• Storage materials: Light-protective refrigerated storage appropriate to the validated formulation.
• Sharps container: Use when transfer needles are part of the preparation workflow.

View Supplier

Published Human Intranasal Semax Dosage Research

Human Semax research has primarily used intranasal drops or measured intranasal solution. The published amount cannot be separated from the study population, formulation, device, or research objective, so the rows below are evidence summaries rather than a universal Semax dosing recommendation.

Evidence boundary: These studies differ substantially in population, concentration, duration, co-treatments, and outcomes. Their published amounts should not be combined into one “standard” schedule.

Semax Nasal Spray Dosage Calculations

A Semax nasal spray calculation requires two verified inputs: the measured final solution volume and the actuator output. Pharmaceutical literature reports pump volumes from about 0.025 mL to 0.20 mL per spray, so a nominal bottle size cannot establish the delivered amount^[5].

Core Formula

mcg per spray = (10,000 mcg ÷ final volume in mL) × verified mL per spray

nominal sprays = final volume in mL ÷ verified mL per spray

FDA nasal-product guidance emphasizes priming, dose uniformity, pump delivery, and performance testing because device behavior affects the amount released from each actuation^[6].

What Is Semax Peptide?

Semax is a synthetic peptide and heptapeptide with the amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was originally developed in Russia from the ACTH(4–10) fragment while avoiding the hormonal activity of full-length adrenocorticotropic hormone^[7]. Human studies have evaluated intranasal Semax in healthy volunteers and condition-specific neurological settings, while much of the mechanistic literature remains preclinical.

Research has examined brain-derived neurotrophic factor (BDNF), neurotrophic signaling, dopaminergic pathways, gene expression, attention, cognitive function, cognitive performance, functional connectivity, and neuroprotection. Secondary sources sometimes describe Semax as a nootropic or discuss cognitive enhancement, brain health, and mental performance, but those phrases exceed what small, heterogeneous human studies can establish^[1][2][7].

Human Findings and Evidence Limits

• Healthy-volunteer research: Small studies reported changes in attention, operator performance, EEG measures, or functional connectivity after intranasal exposure^[1][2].
• Condition-specific research: Stroke, head-injury, peptic-ulcer, and motor-neuron-disease studies used very different protocols and often evaluated Semax alongside other care^{[3][10][11][12]}.
• Reported effects: Cognitive and neurological findings were measured with different endpoints, so results cannot be pooled into one claim about potential benefits.
• No universal dose-response curve: The literature does not establish that one intranasal amount, spray count, or cycle applies across research objectives.
• Formulation matters: A custom solution made from lyophilized material is not automatically equivalent to the preserved 0.1% or 1% nasal-drop products described in foreign literature.

Safety and Regulatory Status

Semax is not an FDA-approved drug in the United States. FDA’s current bulk-substance safety information identifies insufficient safety data and potential immunogenicity risks related to aggregation and peptide impurities for Semax prepared by compounding pharmacies^[9].

Published and foreign-label sources describe nasal irritation among the potential side effects, but the available literature is too heterogeneous to define a complete adverse-effect profile or a favorable safety profile for custom nasal preparations. Research records should capture formulation, concentration, actuator, exposure, nasal condition, and unexpected observations.

Research Controls That Affect Nasal Delivery

• Pump specification: Record the stated and independently checked mL per full actuation.
• Priming status: Document first-use priming, repriming, missed sprays, and tail-off near bottle exhaustion.
• Final volume: Measure the solution volume rather than relying on the bottle-capacity mark.
• Formulation: Record the vehicle, preservative status, peptide concentration, and container compatibility.
• Nasal condition: Document congestion, irritation, or other conditions that could change deposition on the nasal mucosa.

Nasal Actuator Technique for Research Records

1. Confirm the labeled concentration and verified actuator output.
2. Prime or reprime the pump exactly as the device manufacturer specifies.
3. Keep bottle orientation, stroke length, and actuation force consistent.
4. Record every actuation, including priming sprays and incomplete strokes.
5. Clean the nozzle with a device-compatible method, replace the cap, and return the bottle to its documented storage condition.

Semax Storage and Stability Notes

Pure Lab Peptides lists the lyophilized 10 mg vial for storage at -20°C and the reconstituted material at 4°C for up to four weeks, or -20°C for up to six months^[8]. A custom multidose nasal preparation also depends on vehicle sterility, preservative status, container closure, and repeated pump use; the supplier’s peptide-stability statement does not by itself validate microbiological stability in every nasal bottle.

Label the prepared bottle with the peptide mass, measured final volume, concentration, actuator output, preparation date, and storage condition. Protect it from light and avoid unnecessary warming.

Semax Dosage FAQ

How much Semax is in one 0.10 mL spray?

With a 10 mg vial measured to 5 mL, one verified 0.10 mL spray contains 200 mcg. At a 10 mL final volume, the same verified spray contains 100 mcg.

How many sprays are in a 10 mg Semax bottle?

Theoretical counts are 50 sprays from 5 mL or 100 sprays from 10 mL when the actuator releases exactly 0.10 mL. Priming, residual volume, and pump tail-off reduce the usable count.

Is intranasal Semax the same as injectable Semax?

No. The human studies summarized here used intranasal administration. Route, formulation, absorption, and measurement differ, so intranasal amounts cannot be converted into an injection or subcutaneous injection protocol.

Does research establish one Semax cycle length?

No. A research peptide protocol should retain the duration and population from its source; the literature does not establish one universal cycle length.

How long did published Semax protocols last?

Published human protocols ranged from a single exposure to short multi-day courses and repeated condition-specific courses^{[2][3][10][12]}. Duration must remain attached to the original study context.

Are Semax and N-acetyl Semax the same compound?

No. Semax, N-acetyl Semax amidate, and other analogs have different structures and should not be treated as interchangeable in a dosage guide or calculation.